查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
头孢曲松的全球市场:各适应症 - 产业分析，规模，占有率，成长，趋势，预测(2022年～2031年)
市场调查报告书
商品编码
1208548

头孢曲松的全球市场:各适应症 - 产业分析，规模，占有率，成长，趋势，预测(2022年～2031年)

Ceftriaxone Market (Indication: Urinary Tract Infections, Intra-abdominal Infections, Endocarditis, Acute Bacterial Otitis Media, Meningitis, Pneumonia, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日期: | 出版商: Transparency Market Research | 英文 170 Pages | 商品交期: 2-10个工作天内

价格

本报告提供全球头孢曲松市场相关调查分析，提供市场趋势，市场区隔分析，地区分析，企业简介等资讯。

目录

第1章 序文

第2章 前提条件与调查手法

第3章 摘要整理

  • 市场概要
  • 简介

第4章 市场动态

  • 促进因素
  • 阻碍因素
  • 机会
  • 全球头孢曲松市场预测
  • 全球头孢曲松市场预测

第5章 市场预测

  • 主要市场趋势
  • 法规情势:各地区
  • COVID-19大流行病对产业的影响(价值链与短/中/长期的影响)

第6章 全球头孢曲松市场分析与预测:各适应症

  • 简介
  • 全球头孢曲松的市场金额占有率与魅力分析:各适应症
  • 全球头孢曲松市场预测:各适应症
    • 泌尿道感染
    • 腹腔内感染疾病
    • 心内膜炎
    • 急性细菌性中耳炎
    • 脑膜炎
    • 肺炎
    • 其他

第7章 全球头孢曲松市场分析与预测:各流通管道

  • 简介
  • 全球头孢曲松的市场金额占有率分析:各流通管道
  • 全球头孢曲松市场预测:各流通管道
    • 医院药局
    • 零售药局
    • 线上药局
  • 全球头孢曲松市场分析:各流通管道

第8章 全球头孢曲松市场分析:各地区

  • 全球头孢曲松市场分析:各地区
  • 全球头孢曲松的市场金额占有率与魅力分析:各地区
  • 全球头孢曲松市场预测:各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美
    • 中东·非洲

第9章 北美的头孢曲松市场分析

  • 北美的头孢曲松市场概要
  • 北美的头孢曲松的市场金额占有率与魅力分析:各国
  • 北美的头孢曲松市场预测:各国
    • 美国
    • 加拿大
  • 北美的头孢曲松的市场金额占有率与魅力分析:各适应症
  • 北美的头孢曲松市场预测:各适应症
  • 北美的头孢曲松的市场金额占有率与魅力分析:各流通管道
  • 北美的头孢曲松市场预测:各流通管道

第10章 欧洲的头孢曲松市场分析

第11章 亚太地区的头孢曲松市场分析

第12章 南美的头孢曲松市场分析

第13章 中东·非洲的头孢曲松市场分析

第14章 竞争分析

  • 竞争矩阵
  • 市场占有率分析:各企业(2021年)
  • 企业简介
    • Hikma Pharmaceuticals plc
    • Qilu Pharmaceutical Co. Ltd.
    • Novartis AG
    • Baxter International, Inc.
    • Aurobindo Pharma
    • ACS DOBFAR S.P.A.
    • Orchid Pharma
    • Nectar Lifesciences Ltd.
    • Lupin Pharmaceuticals, Inc.
Product Code: TMRGL85274

The report provides revenue of the global ceftriaxone market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global ceftriaxone market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the ceftriaxone market.

The report delves into the competitive landscape of the global ceftriaxone market. Key players operating in the global ceftriaxone market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global ceftriaxone market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Report Scope and Market Segmentation
  • 1.2. Research Highlights

2. Assumptions and Research Methodology

  • 2.1. Assumptions and Acronyms Used
  • 2.2. Research Methodology

3. Executive Summary

  • 3.1. Market Overview
  • 3.2. Introduction

4. Market Dynamics

  • 4.1. Drivers
  • 4.2. Restraints
  • 4.3. Opportunity
  • 4.4. Global Ceftriaxone Market Forecast
  • 4.5. Global Ceftriaxone Market Outlook

5. Market Outlook

  • 5.1. Key Market Trends
  • 5.2. Regulatory Scenario, by Region
  • 5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Ceftriaxone Market Analysis and Forecast, by Indication

  • 6.1. Introduction
  • 6.2. Global Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
  • 6.3. Global Ceftriaxone Market Forecast, by Indication
    • 6.3.1. Urinary Tract Infections
    • 6.3.2. Intra-abdominal Infections
    • 6.3.3. Endocarditis
    • 6.3.4. Acute Bacterial Otitis Media
    • 6.3.5. Meningitis
    • 6.3.6. Pneumonia
    • 6.3.7. Others

7. Global Ceftriaxone Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Global Ceftriaxone Market Value Share Analysis, by Distribution Channel
  • 7.3. Global Ceftriaxone Market Forecast, by Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. Online Pharmacies
  • 7.4. Global Ceftriaxone Market Analysis, by Distribution Channel

8. Global Ceftriaxone Market Analysis, by Region

  • 8.1. Global Ceftriaxone Market Analysis, by Region
  • 8.2. Global Ceftriaxone Market Value Share and Attractiveness Analysis, by Region
  • 8.3. Global Ceftriaxone Market Forecast, by Region
    • 8.3.1. North America
    • 8.3.2. Europe
    • 8.3.3. Asia Pacific
    • 8.3.4. Latin America
    • 8.3.5. Middle East & Africa

9. North America Ceftriaxone Market Analysis

  • 9.1. North America Ceftriaxone Market Overview
  • 9.2. North America Ceftriaxone Market Value Share and Attractiveness Analysis, by Country
  • 9.3. North America Ceftriaxone Market Forecast, by Country
    • 9.3.1. U.S.
    • 9.3.2. Canada
  • 9.4. North America Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
  • 9.5. North America Ceftriaxone Market Forecast, by Indication
    • 9.5.1. Urinary Tract Infections
    • 9.5.2. Intra-abdominal Infections
    • 9.5.3. Endocarditis
    • 9.5.4. Acute Bacterial Otitis Media
    • 9.5.5. Meningitis
    • 9.5.6. Pneumonia
    • 9.5.7. Others
  • 9.6. North America Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
  • 9.7. North America Ceftriaxone Market Forecast, by Distribution Channel
    • 9.7.1. Hospital Pharmacies
    • 9.7.2. Retail Pharmacies
    • 9.7.3. Online Pharmacies

10. Europe Ceftriaxone Market Analysis

  • 10.1. Europe Ceftriaxone Market Overview
  • 10.2. Europe Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
  • 10.3. Europe Ceftriaxone Market Forecast, by Country/Sub-region
    • 10.3.1. Germany
    • 10.3.2. U.K.
    • 10.3.3. France
    • 10.3.4. Italy
    • 10.3.5. Spain
    • 10.3.6. Rest of Europe
  • 10.4. Europe Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
  • 10.5. Europe Ceftriaxone Market Forecast, by Indication
    • 10.5.1. Urinary Tract Infections
    • 10.5.2. Intra-abdominal Infections
    • 10.5.3. Endocarditis
    • 10.5.4. Acute Bacterial Otitis Media
    • 10.5.5. Meningitis
    • 10.5.6. Pneumonia
    • 10.5.7. Others
  • 10.6. Europe Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
  • 10.7. Europe Ceftriaxone Market Forecast, by Distribution Channel
    • 10.7.1. Hospital Pharmacies
    • 10.7.2. Retail Pharmacies
    • 10.7.3. Online Pharmacies

11. Asia Pacific Ceftriaxone Market Analysis

  • 11.1. Asia Pacific Ceftriaxone Market Overview
  • 11.2. Asia Pacific Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
  • 11.3. Asia Pacific Ceftriaxone Market Forecast, by Country/Sub-region
    • 11.3.1. China
    • 11.3.2. India
    • 11.3.3. Japan
    • 11.3.4. Australia & New Zealand
    • 11.3.5. Rest of Asia Pacific
  • 11.4. Asia Pacific Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
  • 11.5. Asia Pacific Ceftriaxone Market Forecast, by Indication
    • 11.5.1. Urinary Tract Infections
    • 11.5.2. Intra-abdominal Infections
    • 11.5.3. Endocarditis
    • 11.5.4. Acute Bacterial Otitis Media
    • 11.5.5. Meningitis
    • 11.5.6. Pneumonia
    • 11.5.7. Others
  • 11.6. Asia Pacific Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
  • 11.7. Asia Pacific Ceftriaxone Market Forecast, by Distribution Channel
    • 11.7.1. Hospital Pharmacies
    • 11.7.2. Retail Pharmacies
    • 11.7.3. Online Pharmacies

12. Latin America Ceftriaxone Market Analysis

  • 12.1. Latin America Ceftriaxone Market Overview
  • 12.2. Latin America Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
  • 12.3. Latin America Ceftriaxone Market Forecast, by Country/Sub-region
    • 12.3.1. Brazil
    • 12.3.2. Mexico
    • 12.3.3. Rest of Latin America
  • 12.4. Latin America Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
  • 12.5. Latin America Ceftriaxone Market Forecast, by Indication
    • 12.5.1. Urinary Tract Infections
    • 12.5.2. Intra-abdominal Infections
    • 12.5.3. Endocarditis
    • 12.5.4. Acute Bacterial Otitis Media
    • 12.5.5. Meningitis
    • 12.5.6. Pneumonia
    • 12.5.7. Others
  • 12.6. Latin America Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
  • 12.7. Latin America Ceftriaxone Market Forecast, by Distribution Channel
    • 12.7.1. Hospital Pharmacies
    • 12.7.2. Retail Pharmacies
    • 12.7.3. Online Pharmacies

13. Middle East & Africa Ceftriaxone Market Analysis

  • 13.1. Middle East & Africa Ceftriaxone Market Overview
  • 13.2. Middle East & Africa Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
  • 13.3. Middle East & Africa Ceftriaxone Market Forecast, by Country/Sub-region
    • 13.3.1. GCC Countries
    • 13.3.2. South Africa
    • 13.3.3. Rest of Middle East & Africa
  • 13.4. Middle East & Africa Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
  • 13.5. Middle East & Africa Ceftriaxone Market Forecast, by Indication
    • 13.5.1. Urinary Tract Infections
    • 13.5.2. Intra-abdominal Infections
    • 13.5.3. Endocarditis
    • 13.5.4. Acute Bacterial Otitis Media
    • 13.5.5. Meningitis
    • 13.5.6. Pneumonia
    • 13.5.7. Others
  • 13.6. Middle East & Africa Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
  • 13.7. Middle East & Africa Ceftriaxone Market Forecast, by Distribution Channel
    • 13.7.1. Hospital Pharmacies
    • 13.7.2. Retail Pharmacies
    • 13.7.3. Online Pharmacies

14. Competitive Analysis

  • 14.1. Competition Matrix
  • 14.2. Market Share Analysis, by Company, 2021
  • 14.3. Company Profile
    • 14.3.1. Hikma Pharmaceuticals plc
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. Financial Overview
      • 14.3.1.4. Strategic Overview
      • 14.3.1.5. SWOT Analysis
    • 14.3.2. Qilu Pharmaceutical Co. Ltd.
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. Financial Overview
      • 14.3.2.4. Strategic Overview
      • 14.3.2.5. SWOT Analysis
    • 14.3.3. Novartis AG
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. Financial Overview
      • 14.3.3.4. Strategic Overview
      • 14.3.3.5. SWOT Analysis
    • 14.3.4. Baxter International, Inc.
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. Financial Overview
      • 14.3.4.4. Strategic Overview
      • 14.3.4.5. SWOT Analysis
    • 14.3.5. Aurobindo Pharma
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. Strategic Overview
      • 14.3.5.4. SWOT Analysis
    • 14.3.6. ACS DOBFAR S.P.A.
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. Strategic Overview
      • 14.3.6.4. SWOT Analysis
    • 14.3.7. Orchid Pharma
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. Strategic Overview
      • 14.3.7.4. SWOT Analysis
    • 14.3.8. Nectar Lifesciences Ltd.
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. Financial Overview
      • 14.3.8.4. Strategic Overview
      • 14.3.8.5. SWOT Analysis
    • 14.3.9. Lupin Pharmaceuticals, Inc.
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. Financial Overview
      • 14.3.9.4. Strategic Overview
      • 14.3.9.5. SWOT Analysis

List of Tables

  • Table 01: Global Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 02: Global Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 03: Global Ceftriaxone Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 04: North America Ceftriaxone Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 05: North America Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 06: North America Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 07: Europe Ceftriaxone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 08: Europe Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 09: Europe Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 10: Asia Pacific Ceftriaxone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 11: Asia Pacific Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 12: Asia Pacific Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Latin America Ceftriaxone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Latin America Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 15: Latin America Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 16: Middle East & Africa Ceftriaxone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Middle East & Africa Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 18: Middle East & Africa Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Ceftriaxone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 02: Global Ceftriaxone Market Value Share, by Indication (2021)
  • Figure 03: Global Ceftriaxone Market Value Share, by Distribution Channel (2021)
  • Figure 04: Global Ceftriaxone Market Value Share, by Region (2021)
  • Figure 05: Global Ceftriaxone Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 06: Global Ceftriaxone Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 07: Global Ceftriaxone Market Revenue (US$ Mn), by Urinary Tract Infections, 2017-2031
  • Figure 08: Global Ceftriaxone Market Revenue (US$ Mn), by Intra-abdominal Infections, 2017-2031
  • Figure 09: Global Ceftriaxone Market Revenue (US$ Mn), by Endocarditis, 2017-2031
  • Figure 10: Global Ceftriaxone Market Revenue (US$ Mn), by Acute Bacterial Otitis Media, 2017-2031
  • Figure 11: Global Ceftriaxone Market Revenue (US$ Mn), by Meningitis, 2017-2031
  • Figure 12: Global Ceftriaxone Market Revenue (US$ Mn), by Pneumonia, 2017-2031
  • Figure 13: Global Ceftriaxone Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 14: Global Ceftriaxone Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 15: Global Ceftriaxone Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 16: Global Ceftriaxone Market Revenue (US$ Mn), by Hospital Pharmacies, 2017-2031
  • Figure 17: Global Ceftriaxone Market Revenue (US$ Mn), by Retail Pharmacies, 2017-2031
  • Figure 18: Global Ceftriaxone Market Revenue (US$ Mn), by Online Pharmacies, 2017-2031
  • Figure 19: Global Ceftriaxone Market Value Share Analysis, by Region, 2021 and 2031
  • Figure 20: Global Ceftriaxone Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 21: North America Ceftriaxone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 22: North America Ceftriaxone Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 23: North America Ceftriaxone Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 24: North America Ceftriaxone Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 25: North America Ceftriaxone Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 26: North America Ceftriaxone Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 27: North America Ceftriaxone Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 28: Europe Ceftriaxone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 29: Europe Ceftriaxone Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 30: Europe Ceftriaxone Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 31: Europe Ceftriaxone Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 32: Europe Ceftriaxone Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 33: Europe Ceftriaxone Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 34: Europe Ceftriaxone Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 35: Asia Pacific Ceftriaxone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 36: Asia Pacific Ceftriaxone Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 37: Asia Pacific Ceftriaxone Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 38: Asia Pacific Ceftriaxone Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 39: Asia Pacific Ceftriaxone Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 40: Asia Pacific Ceftriaxone Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 41: Asia Pacific Ceftriaxone Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 42: Latin America Ceftriaxone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 43: Latin America Ceftriaxone Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 44: Latin America Ceftriaxone Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 45: Latin America Ceftriaxone Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 46: Latin America Ceftriaxone Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 47: Latin America Ceftriaxone Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 48: Latin America Ceftriaxone Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 49: Middle East & Africa Ceftriaxone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 50: Middle East & Africa Ceftriaxone Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 51: Middle East & Africa Ceftriaxone Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 52: Middle East & Africa Ceftriaxone Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 53: Middle East & Africa Ceftriaxone Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 54: Middle East & Africa Ceftriaxone Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 55: Middle East & Africa Ceftriaxone Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 56: Global Ceftriaxone Market Share, by Company, 2021